ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Atomwise, an artificial intelligence–based drug discovery firm, has formed a research pact with Sanofi in which the partners will use Atomwise’s AtomNet computational platform on up to five drug targets. Sanofi will pay Atomwise $20 million, plus possible milestones, to identify, synthesize, and advance small molecules that will be exclusive to Sanofi. Atomwise’s platform employs AI algorithms for structure-based drug design and to search its virtual library of more than 3 trillion compounds that can be synthesized.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter